Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.03.061. Online ahead of print.ABSTRACTThe ComFluCOV trial randomized 679 participants to receive an age-appropriate influenza vaccine, or placebo, alongside their second COVID-19 vaccine. Concomitant administration was shown to be safe, and to preserve systemic immune responses to both vaccines. Here we report on a secondary outcome of the trial investigating SARS-CoV-2-specific mucosal antibody responses. Anti-spike IgG and IgA levels in saliva were measured with in-house ELISAs. Concomitant administration of an influenza vaccine did not affect salivar...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Holly E Baum Russell Thirard Alice Halliday Sarah Baos Amy C Thomas Rosie A Harris Elizabeth Oliver Lucy Culliford Benjamin Hitchings Rachel Todd Kapil Gupta Anu Goenka Adam Finn Chris A Rogers Rajeka Lazarus ComFluCOV Trial Group Source Type: research
Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022
CONCLUSIONS: Our study of the long-term serological course of SARS-CoV-2 in a nursing home showed that the first SARS-CoV-2 booster vaccine was essential for maintaining antiviral antibody levels. Hybrid immunity sustained SARS-CoV-2 immunity at the highest level. In critical settings such as nursing homes, monitoring the SARS-CoV-2 immune status may guide booster vaccinations.PMID:38579325 | DOI:10.57187/s.3502 (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Lisa Perrig Irene A Abela Nicolas Banholzer Annette Audig é Selina Epp Catrina Mugglin Kathrin Z ürcher Matthias Egger Alexandra Trkola Lukas Fenner Source Type: research
Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022
CONCLUSIONS: Our study of the long-term serological course of SARS-CoV-2 in a nursing home showed that the first SARS-CoV-2 booster vaccine was essential for maintaining antiviral antibody levels. Hybrid immunity sustained SARS-CoV-2 immunity at the highest level. In critical settings such as nursing homes, monitoring the SARS-CoV-2 immune status may guide booster vaccinations.PMID:38579325 | DOI:10.57187/s.3502 (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - April 5, 2024 Category: General Medicine Authors: Lisa Perrig Irene A Abela Nicolas Banholzer Annette Audig é Selina Epp Catrina Mugglin Kathrin Z ürcher Matthias Egger Alexandra Trkola Lukas Fenner Source Type: research
News at a glance: Giant telescope camera complete, limits to Paxlovid benefits, and missing battlefield bones
ASTRONOMY
Biggest ever digital camera heads to Chile
Skip slideshow
Researchers at the SLAC National Accelerator Laboratory have finished building the biggest ever astronomical camera. It will create a movie of the universe, imaging the whole southern sky in unprecedented detail every 3 days.
Jacqueline Ramseyer Orrell/SLAC National Accelerator Laboratory
Researchers install the first of 21 arrays of image sensors that together make up the camer...
Source: Science of Aging Knowledge Environment - April 4, 2024 Category: Geriatrics Source Type: research
Evaluation of the hematological and immunological markers after the first and second doses of BNT162b2 mRNA vaccine
CONCLUSIONS: We can conclude that the Pfizer/BioNTech vaccine produced a more potent T-cell response than humoral ones.PMID:38567619 | DOI:10.26355/eurrev_202403_35766 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 3, 2024 Category: Drugs & Pharmacology Authors: M Rafeeq M S Jabir H M Al-Kuraishy Z M A Jeddoa S F Jawad M A A Najm A F Almulla E Elekhnawy J Z Tayyeb A Turkistani B A Alsfouk G E Batiha Source Type: research
Evaluation of the hematological and immunological markers after the first and second doses of BNT162b2 mRNA vaccine
CONCLUSIONS: We can conclude that the Pfizer/BioNTech vaccine produced a more potent T-cell response than humoral ones.PMID:38567619 | DOI:10.26355/eurrev_202403_35766 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 3, 2024 Category: Drugs & Pharmacology Authors: M Rafeeq M S Jabir H M Al-Kuraishy Z M A Jeddoa S F Jawad M A A Najm A F Almulla E Elekhnawy J Z Tayyeb A Turkistani B A Alsfouk G E Batiha Source Type: research
Evaluation of the hematological and immunological markers after the first and second doses of BNT162b2 mRNA vaccine
CONCLUSIONS: We can conclude that the Pfizer/BioNTech vaccine produced a more potent T-cell response than humoral ones.PMID:38567619 | DOI:10.26355/eurrev_202403_35766 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 3, 2024 Category: Drugs & Pharmacology Authors: M Rafeeq M S Jabir H M Al-Kuraishy Z M A Jeddoa S F Jawad M A A Najm A F Almulla E Elekhnawy J Z Tayyeb A Turkistani B A Alsfouk G E Batiha Source Type: research
Evaluation of the hematological and immunological markers after the first and second doses of BNT162b2 mRNA vaccine
CONCLUSIONS: We can conclude that the Pfizer/BioNTech vaccine produced a more potent T-cell response than humoral ones.PMID:38567619 | DOI:10.26355/eurrev_202403_35766 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 3, 2024 Category: Drugs & Pharmacology Authors: M Rafeeq M S Jabir H M Al-Kuraishy Z M A Jeddoa S F Jawad M A A Najm A F Almulla E Elekhnawy J Z Tayyeb A Turkistani B A Alsfouk G E Batiha Source Type: research
